Physicians' Academy for Cardiovascular Education

NT-proBNP measured early after high-risk MI associated with further CV outcomes

Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial

Literature - Jering KS, Claggett BL, Pfeffer MA, et al. - Circ Heart Fail. 2023 May;16(5):e010259. doi: 10.1161/CIRCHEARTFAILURE.122.010259.


Patients who have experienced an acute myocardial infarction (MI) have an increased risk of further MI, stroke, HF and death, especially sudden death [1-5]. However, only a subset of patients, even after high-risk MI, experience these events, indicating a need for risk stratification in post-MI surveillance and treatment [4-9]. NT-proBNP is used as a prognostic marker of death and HF across multiple populations [10-11]. It remains unclear what the relationship is between NT-proBNP and recurrent MI and stroke in patients with ACS.

Aim of the study

The investigators examined the relationship between NT-proBNP and CV outcomes in patients following high-risk acute MI from the PARADISE-MI trial.



PARADISE-MI (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction) was a multicenter, double-blind, active comparator, randomized trial that compared the efficacy and safety of sacubitril/valsartan (97 mg sacubitril/93 mg valsartan twice daily) with ramipril (5 mg twice daily) in adult patients with a spontaneous acute MI complicated with LVEF ≤40% and/or pulmonary congestion, and ≥1 of 8 risk-augmenting factors. Patients with prior history of HF were excluded. In this prespecified subanalysis, a total of 1129 patients were included. Blood samples for NT-proBNP and hs-cTnT measurements were obtained within the first week of an MI. Data were analyzed with NT-proBNP as continuous variable or according to NT-proBNP quartiles (quartile 1: ≤896 ng/L; quartile 2: ≤897-1757 ng/L; quartile 3: 1758-3462 ng/L; quartile 4: >3462 ng/L). The median follow-up period was 29 months.


The primary outcome was a composite of CV mortality or incident HF (hospitalization or outpatient episode of symptomatic HF), analyzed as time-to-first event. Key secondary outcomes were CV mortality; HF hospitalization; all-cause mortality; and the composite of CV mortality, nonfatal MI or stroke.

Main results

NT-proBNP and clinical outcomes

Modeling risk for all-cause mortality


In a prespecified analysis using data of the PARADISE-MI trial, NT-proBNP measured within the first week of a high-risk MI was associated with the primary composite outcome of CV mortality or incident HF, independent of hs-cTnT. Moreover, model discrimination for all-cause mortality with only early NT-proBNP measurements performed similar to well-validated risk scores such as GRACE 2.0 or TRA 2°P-TIMI in this high-risk post-MI patient population. The authors state that “our findings seem to support the recommendation for NT-proBNP measurement following MI to assist in risk stratification”.


Show references

Find this article online at Circ Heart Fail.

Share this page with your colleagues and friends: